OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.210
+0.004 (0.12%)
Aug 3, 2026, 1:50 PM CET
OSE Immunotherapeutics Revenue
In the year 2025, OSE Immunotherapeutics had annual revenue of 2.62M EUR, down -96.25%. OSE Immunotherapeutics had revenue of 1.30M in the half year ending December 31, 2025, with 49.14% growth.
Revenue
2.62M
Revenue Growth
-96.25%
P/S Ratio
28.02
Revenue / Employee
42.05K
Employees
64
Market Cap
75.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.62M | -67.26M | -96.25% |
| Dec 31, 2024 | 69.88M | 67.65M | 3,037.72% |
| Dec 31, 2023 | 2.23M | -16.08M | -87.83% |
| Dec 31, 2022 | 18.30M | -8.00M | -30.43% |
| Dec 31, 2021 | 26.31M | 15.89M | 152.51% |
| Dec 31, 2020 | 10.42M | -15.53M | -59.86% |
| Dec 31, 2019 | 25.95M | 1.50M | 6.12% |
| Dec 31, 2018 | 24.46M | 17.77M | 266.00% |
| Dec 31, 2017 | 6.68M | 6.30M | 1,644.65% |
| Dec 31, 2016 | 383.00K | 379.00K | 9,475.00% |
| Dec 31, 2015 | 4.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 65.14M |
| Nicox | 16.77M |
| Fermentalg | 13.38M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Advicenne | 6.40M |
| Sensorion | 5.81M |
| MaaT Pharma | 4.52M |
OSE Immunotherapeutics News
- 7 weeks ago - OSE Immunotherapeutics Transcript: Status update - Transcripts
- 2 months ago - OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document - GlobeNewsWire
- 2 months ago - OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing - GlobeNewsWire
- 2 months ago - OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer - GlobeNewsWire
- 3 months ago - OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position - GlobeNewsWire
- 3 months ago - OSE Immunotherapeutics Earnings release: H2 2025 - Filings
- 3 months ago - OSE Immunotherapeutics Annual report: H2 2025 - Filings
- 3 months ago - OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients - GlobeNewsWire